Hólyagrák: vizsgálatok itt: Csehország
8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
- Where
- Hradec Králové, Olomouc, Prague
- Életkor
- 18 év and over
- People
- 641 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06319820 - 3. fázisTaking peopleTrial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
- Where
- Kroměříž, Liberec I-Stare Mesto, Prague, Prague 6
- Életkor
- 18 év and over
- People
- 454 worldwide
- Run by
- Ferring Pharmaceuticals
See details and how to joinNCT06510374 · EU 2024-512029-10-00 - 3. fázisTaking peopleA Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
- Where
- Kroměříž, Liberec I-Stare Mesto, Prague, Prague 6
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Ferring Pharmaceuticals
See details and how to joinNCT06545955 · EU 2024-512177-27-01 - 2/3. fázisTaking peopleDato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.
- Where
- Olomouc, Prague, Prague 2
- Életkor
- 18 év and over
- People
- 343 worldwide
- Run by
- Daiichi Sankyo Inc.
See details and how to join2024-516906-47-00 · EU 2024-516906-47-00 - 3. fázisTaking peopleA Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Where
- Brno, Hradec Králové, Olomouc, Prague
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07218380 · EU 2025-522855-25-00 - 3. fázisTaking peopleA Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer
- Where
- Prague
- Életkor
- 18 év and over
- People
- 194
- Run by
- Hamlet Pharma AB
See details and how to joinNCT07804056 · EU 2026-525531-16-00 - 3. fázisTaking peopleRoll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
- Where
- Olomouc
- Életkor
- 18 év and over
- People
- 87 worldwide
- Run by
- Astrazeneca AB
See details and how to joinNCT05303532 · EU 2023-507337-22-00 - 2/3. fázisTaking peoplePhase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
- Where
- Brno, Hradec Králové, Prague
- Életkor
- 18 év and over
- People
- 470 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07106762